Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$120,000.00
Mechanisms of aT-catenin phosphoregulation at the intercalated disc and its impact on the function of healthy and diseased hearts
EF 2024-25
Résumé
Heart failure (HF) is a leading cause of death worldwide. To develop better treatments, we must gain an understanding of the cellular mechanisms underlying heart diseases that lead to HF. One strategy is to investigate common protein modifications that affect protein function, such as phosphorylation. Our lab recently discovered that CTNNA3, a protein involved in cell adhesion between heart muscle cells (cardiomyocytes), is highly phosphorylated at specific sites in HF patients with dilated cardiomyopathy (DCM). Its phosphorylation also affects heart function in mice. However, it is unclear how CTNNA3 is phosphorylated and how it affects cardiomyocytes and the diseased heart. My doctoral research project aims to address these questions.
I hypothesize that manipulating CTNNA3 phosphorylation (C-P) affects both cardiac and cardiomyocyte function through changes to protein localization and protein interactions in the cardiomyocyte. I will test my hypothesis in 3 steps. First, I will use our established drug-screening platform to identify the enzymes responsible for C-P at the DCM-specific sites and drugs that can be used to inhibit/activate them. Second, to determine the downstream effects of C-P, I will assess how changes in C-P affect its interactions with other proteins and the locations of those proteins in mouse hearts. Furthermore, I will measure how cardiomyocyte contractility is affected by changes to C-P. Thirdly, to determine how C-P affects function in diseased hearts, I will measure changes to heart function in heart diseased mice expressing different mutant forms of CTNNA3, each representing different levels of phosphorylation. I will also administer diseased mice with drugs identified in our drug screen to see if manipulating C-P can recover function in diseased hearts.
Ultimately, this research will improve understanding of the cardioprotective effects of C-P and provide insight into therapeutic approaches to improve patient outcomes in heart disease.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518311
Name
Davoudpour Daniel
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Mechanisms of aT-catenin phosphoregulation at the intercalated disc and its impact on the function of healthy and diseased hearts
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cardiomyocyte Biology; Cardiovascular Disease; Cell Biology; Heart Failure; Intercalated Disc; Mass Spectrometry; Protein Biochemistry
Abstract
Heart failure (HF) is a leading cause of death worldwide. To develop better treatments, we must gain an understanding of the cellular mechanisms underlying heart diseases that lead to HF. One strategy is to investigate common protein modifications that affect protein function, such as phosphorylation. Our lab recently discovered that CTNNA3, a protein involved in cell adhesion between heart muscle cells (cardiomyocytes), is highly phosphorylated at specific sites in HF patients with dilated cardiomyopathy (DCM). Its phosphorylation also affects heart function in mice. However, it is unclear how CTNNA3 is phosphorylated and how it affects cardiomyocytes and the diseased heart. My doctoral research project aims to address these questions.
I hypothesize that manipulating CTNNA3 phosphorylation (C-P) affects both cardiac and cardiomyocyte function through changes to protein localization and protein interactions in the cardiomyocyte. I will test my hypothesis in 3 steps. First, I will use our established drug-screening platform to identify the enzymes responsible for C-P at the DCM-specific sites and drugs that can be used to inhibit/activate them. Second, to determine the downstream effects of C-P, I will assess how changes in C-P affect its interactions with other proteins and the locations of those proteins in mouse hearts. Furthermore, I will measure how cardiomyocyte contractility is affected by changes to C-P. Thirdly, to determine how C-P affects function in diseased hearts, I will measure changes to heart function in heart diseased mice expressing different mutant forms of CTNNA3, each representing different levels of phosphorylation. I will also administer diseased mice with drugs identified in our drug screen to see if manipulating C-P can recover function in diseased hearts.
Ultimately, this research will improve understanding of the cardioprotective effects of C-P and provide insight into therapeutic approaches to improve patient outcomes in heart disease.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Davoudpour, Daniel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~